In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
Veterinary dermatology focuses on the diagnosis and treatment of complex skin diseases, including skin infections, allergies, and ear disease. “Common” skin issues like itchy skin and ear infections ...
Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
TipRanks on MSN
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt
InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...
InflaRx N.V. (NASDAQ:IFRX) on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma ...
The Global Burden of Disease (GBD) Study 2021 reported 44.84 million disability-adjusted life years (DALYs) because of skin and subcutaneous diseases. Researchers utilized data from the GBD Study 2021 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback